Axitinib is an oral VEGFR and kinase inhibitor used for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).
- Mechanism
- Curator reviewed
Axitinib selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.
- Primary indication
- Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.Curator reviewed · 4 structured indications
- Formula / weight
- C22H18N4OS · 386.47 g/mol (avg)
- First approval
- Canada, 2012 · United States, 2012 · European Union, 2016
- Also known as
- N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
- Code names
- AG-013736 · AG-13736 · AR-14034 · OTX-TKI
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
RITAVMQDGBJQJZ-FMIVXFBMSA-NSMILESCNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1Transporters
What you can answer from here — as of September 15, 2026
7Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
3TransportersSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Axitinib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account